Recent advances for FLAP inhibitors
D Pettersen, Ö Davidsson, C Whatling - Bioorganic & medicinal chemistry …, 2015 - Elsevier
D Pettersen, Ö Davidsson, C Whatling
Bioorganic & medicinal chemistry letters, 2015•ElsevierA number of FLAP inhibitors have been progressed to clinical trials for respiratory and other
inflammatory indications but so far no drug has reached the market. With this Digest we
assess the opportunity to develop FLAP inhibitors for indications beyond respiratory
disease, and in particular for atherosclerotic cardiovascular disease. We also show how
recently disclosed FLAP inhibitors have structurally evolved from the first generation FLAP
inhibitors paving the way for new compound classes.
inflammatory indications but so far no drug has reached the market. With this Digest we
assess the opportunity to develop FLAP inhibitors for indications beyond respiratory
disease, and in particular for atherosclerotic cardiovascular disease. We also show how
recently disclosed FLAP inhibitors have structurally evolved from the first generation FLAP
inhibitors paving the way for new compound classes.
Abstract
A number of FLAP inhibitors have been progressed to clinical trials for respiratory and other inflammatory indications but so far no drug has reached the market. With this Digest we assess the opportunity to develop FLAP inhibitors for indications beyond respiratory disease, and in particular for atherosclerotic cardiovascular disease. We also show how recently disclosed FLAP inhibitors have structurally evolved from the first generation FLAP inhibitors paving the way for new compound classes.
Elsevier